Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MEGF0444A · 3 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| A | EXPERIMENTAL | - |
| B | EXPERIMENTAL | - |
| 1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| MEGF0444A | DRUG | Intravenous repeating dose |
| bevacizumab | DRUG | Intravenous repeating dose |
| carboplatin | DRUG | Intravenous repeating dose |
| paclitaxel | DRUG | Intravenous repeating dose |
| placebo | DRUG | Intravenous repeating dose |
Inclusion Criteria: * Histologically or cytologically documented inoperable (Stage IV) or recurrent non-squamous non-small cell lung cancer (NSCLC). Diagnoses of non-squamous NSCLC that are based on sputum cytology alone are not acceptable. Mixed tumors should be categorized according to the predom...
MEGF0444A is an investigational oncology drug being studied for non-squamous non-small cell lung cancer and solid cancers. It is being developed by Roche Holding AG (RHHBY) and is currently in Phase 2 clinical development.
MEGF0444A is a small molecule being studied in oncology. Its specific molecular target has not been disclosed in available clinical trial information.
MEGF0444A is being developed by Roche Holding AG, which trades under the ticker RHHBY. The drug is currently in Phase 2 clinical trials for oncology indications.
MEGF0444A is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied in clinical trials.
MEGF0444A has been studied in three completed clinical trials. NCT01366131 is a Phase 2 trial in non-squamous non-small cell lung cancer. NCT00909740 and NCT01075464 are Phase 1 trials in solid cancers, with the latter combining MEGF0444A with bevacizumab and paclitaxel.
MEGF0444A is also known by the name NILE in the context of a clinical trial. The Phase 2 study NCT01366131 is referred to as the NILE study, evaluating MEGF0444A in combination with carboplatin, paclitaxel, and bevacizumab.